Amir A Toor

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/151942/publications.pdf

Version: 2024-02-01

104	2,857	230014	206121
papers	citations	27	51
		h-index	g-index

118	118	118	3312
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	High dose valacyclovir for cytomegalovirus prophylaxis following allogeneic hematopoietic cell transplantation. Journal of Oncology Pharmacy Practice, 2023, 29, 130-137.	0.5	2
2	Dynamical Systems Modeling of Early-Term Immune Reconstitution with Different Antithymocyte Globulin Administration Schedules in Allogeneic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 85.e1-85.e9.	0.6	6
3	Transient left ventricular dysfunction following chimeric antigen receptor Tâ€cellâ€mediated encephalopathy: A form of stress cardiomyopathy. EJHaem, 2022, 3, 231-234.	0.4	2
4	Cancer immunotherapy: Identifying cancer testis antigen peptides to enhance antitumor response.. Journal of Clinical Oncology, 2022, 40, e20022-e20022.	0.8	0
5	Single cell biomass tracking allows identification and isolation of rare targeted therapy-resistant DLBCL cells within a mixed population. Analyst, The, 2021, 146, 1157-1162.	1.7	7
6	What is the minimum adequate busulfan dose for patients with sickle cell disease undergoing reduced intensity conditioning with fludarabine, busulfan, and antiâ€thymocyte globulin?. EJHaem, 2021, 2, 471-474.	0.4	1
7	Increased donor inhibitory KIR with known HLA interactions provide protection from relapse following HLA matched unrelated donor HCT for AML. Bone Marrow Transplantation, 2021, 56, 2714-2722.	1.3	6
8	Recombinant activated factor VII in a patient with intracranial hemorrhage and severe thrombocytopenia. Clinical Case Reports (discontinued), 2021, 9, e04788.	0.2	2
9	KIR-HLA Interactions Lack Clinical Utility in Matched Unrelated Donor Transplantation for AML: An Analysis of the CIBMTR and DRST Registries. Blood, 2021, 138, 419-419.	0.6	1
10	Killer Immunoglobulin-Like Receptor-Ligand Interactions Predict Clinical Outcomes following Unrelated Donor Transplantations. Biology of Blood and Marrow Transplantation, 2020, 26, 672-682.	2.0	10
11	Digital Polymerase Chain Reaction Paired with High-Speed Atomic Force Microscopy for Quantitation and Length Analysis of DNA Length Polymorphisms. ACS Nano, 2020, 14, 15385-15393.	7.3	4
12	Can Graft vs. Leukemia Effect Be Uncoupled From Graft vs. Host Disease? An Examination of Proportions. Frontiers in Immunology, 2020, 11, 777.	2.2	2
13	Risk Stratified Tandem Vs Single Autologous Stem Cell Transplantation for Multiple Myeloma Yields Equivalent Survival. Blood, 2020, 136, 23-24.	0.6	2
14	Targetable immune checkpoint molecules may be significantly differentially expressed in minority ethnicities.. Journal of Clinical Oncology, 2020, 38, 3576-3576.	0.8	4
15	Functional B Cell Reconstitution Following Allogeneic Stem Cell Transplantation. Blood, 2020, 136, 40-40.	0.6	0
16	Favorable Immune Reconstitution in Patients Administered Anti-Thymocyte Globulin (ATG) Early in the Course of Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation. Blood, 2020, 136, 16-17.	0.6	0
17	Safety and Tolerability of Intra-Venous Ascorbic Acid in Allogeneic Hematopoietic Cell Transplant Recipients: A Matched Historical Control Study. Blood, 2020, 136, 29-30.	0.6	1
18	Increased Inhibitory KIR-Ligand Interactions Confer Relapse Protection Following HLA Matched Unrelated Donor HCT for AML. Blood, 2020, 136, 47-47.	0.6	1

#	Article	IF	Citations
19	FLT3 Internal Tandem Duplication Quantitation and Length Analysis By Digital PCR Paired with High-Speed AFM. Blood, 2020, 136, 21-22.	0.6	0
20	A Preliminary Investigation towards the Risk Stratification of Allogeneic Stem Cell Recipients with Respect to the Potential for Development of GVHD via Their Pre-Transplant Plasma Lipid and Metabolic Signature. Cancers, 2019, 11, 1051.	1.7	12
21	Reduced plasma ascorbic acid levels in recipients of myeloablative conditioning and hematopoietic cell transplantation. European Journal of Haematology, 2019, 103, 329-334.	1.1	5
22	T Cell Repertoire Evolution after Allogeneic Bone Marrow Transplantation: An Organizational Perspective. Biology of Blood and Marrow Transplantation, 2019, 25, 868-882.	2.0	15
23	Hematopoietic stem cell mobilization following PDâ€1 blockade: Cytokine release syndrome after transplantation managed with ascorbic acid. European Journal of Haematology, 2019, 103, 134-136.	1.1	8
24	Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy. Leukemia and Lymphoma, 2019, 60, 2733-2743.	0.6	18
25	Registries and artificial intelligence: investing in the future of hematopoietic cell transplantation. Bone Marrow Transplantation, 2019, 54, 477-480.	1.3	7
26	A dynamical systems perspective on chimeric antigen receptor T-cell dosing. Bone Marrow Transplantation, 2019, 54, 485-489.	1.3	6
27	Tumor cell escape from therapy-induced senescence. Biochemical Pharmacology, 2019, 162, 202-212.	2.0	105
28	Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies. Leukemia and Lymphoma, 2018, 59, 2836-2841.	0.6	28
29	The influence of lymphoid reconstitution kinetics on clinical outcomes in allogeneic stem cell transplantation. Leukemia and Lymphoma, 2018, 59, 2973-2981.	0.6	4
30	Reconstituting donor T cells increase their biomass following hematopoietic stem cell transplantation. Analyst, The, 2018, 143, 2479-2485.	1.7	6
31	Determining the Quantitative Principles of T Cell Response to Antigenic Disparity in Stem Cell Transplantation. Frontiers in Immunology, 2018, 9, 2284.	2.2	11
32	Elucidating a Lipidomic and Metabolomic Signature of Gvhd in Recipients of Allogeneic Stem Cell Transplants. Biology of Blood and Marrow Transplantation, 2018, 24, S185-S186.	2.0	1
33	Low-dose splenic irradiation prior to hematopoietic cell transplantation in hypersplenic patients with myelofibrosis. Leukemia and Lymphoma, 2017, 58, 2983-2984.	0.6	14
34	Low Plasma Vitamin C Levels in Patients Undergoing Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, S286-S287.	2.0	4
35	Role of Epigenetic Modification and Immunomodulation in a Murine Prostate Cancer Model. Prostate, 2017, 77, 361-373.	1.2	4
36	Conditioning neoadjuvant therapies for improved immunotherapy of cancer. Biochemical Pharmacology, 2017, 145, 12-17.	2.0	11

#	Article	IF	Citations
37	DNA nanomapping using CRISPR-Cas9 as a programmable nanoparticle. Nature Communications, 2017, 8, 1665.	5.8	27
38	Treatment of acute fibrinous organizing pneumonia following hematopoietic cell transplantation with etanercept. Bone Marrow Transplantation, 2017, 52, 141-143.	1.3	14
39	Sequence homology between HLA-bound cytomegalovirus and human peptides: A potential trigger for alloreactivity. PLoS ONE, 2017, 12, e0178763.	1.1	19
40	Dynamical system modeling to simulate donor T cell response to whole exome sequencing-derived recipient peptides: Understanding randomness in alloreactivity incidence following stem cell transplantation. PLoS ONE, 2017, 12, e0187771.	1.1	41
41	Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells. Journal of Leukocyte Biology, 2016, 100, 625-635.	1.5	39
42	On the organization of human T-cell receptor loci: log-periodic distribution of T-cell receptor gene segments. Journal of the Royal Society Interface, 2016, 13, 20150911.	1.5	6
43	Dynamical System Modeling to Simulate Donor T Cell Response to Whole Exome Sequencing-Derived Recipient Peptides Demonstrates Different Alloreactivity Potential in HLA-Matched and -Mismatched Donorâ€“Recipient Pairs. Biology of Blood and Marrow Transplantation, 2016, 22, 850-861.	2.0	29
44	Dynamical System Modeling of Immune Reconstitution after Allogeneic Stem Cell Transplantation Identifies Patients at Risk for Adverse Outcomes. Biology of Blood and Marrow Transplantation, 2015, 21, 1237-1245.	2.0	28
45	Stem Cell Transplantation as a Dynamical System: Are Clinical Outcomes Deterministic?. Frontiers in Immunology, 2014, 5, 613.	2.2	25
46	In silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem-Cell Transplant Donors and Recipients: Understanding the Quantitative Immunobiology of Allogeneic Transplantation. Frontiers in Immunology, 2014, 5, 529.	2.2	48
47	Whole exome sequencing to estimate alloreactivity potential between donors and recipients in stem cell transplantation. British Journal of Haematology, 2014, 166, 566-570.	1.2	47
48	Etiology of GVHD: Alloreactivity or Impaired Cellular Adaptation?. Immunological Investigations, 2014, 43, 851-857.	1.0	9
49	In Silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem Cell Transplant Donor-Recipient Pairs. Biology of Blood and Marrow Transplantation, 2014, 20, S269-S270.	2.0	1
50	Fractal Organization of the Human T Cell Repertoire in Health and after Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 366-377.	2.0	55
51	An Outcome-Adaptive Allocation Method for Clinical Trials With Dual Binary Objectives. Statistics in Biopharmaceutical Research, 2013, 5, 67-78.	0.6	2
52	Immune Reconstitution In Anti-Thymocyte Globulin Conditioned Unrelated Donor Stem Cell Transplantation. Blood, 2013, 122, 2071-2071.	0.6	2
53	Favorable T Cell Reconstitution In Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation with Low-Dose Rabbit Anti-Thymocyte Globulin and Total Body Irradiation. Blood, 2013, 122, 4577-4577.	0.6	1
54	Whole Exome Sequencing To Estimate Alloreactivity Potential Between Donors and Recipients In Stem Cell Transplantation. Blood, 2013, 122, 150-150.	0.6	1

#	Article	IF	Citations
55	Anti-thymocyte globulin for conditioning in matched unrelated donor hematopoietic cell transplantation provides comparable outcomes to matched related donor recipients. Bone Marrow Transplantation, 2012, 47, 1513-1519.	1.3	26
56	Immunotherapy of Cancer: Reprogramming Tumor-Immune Crosstalk. Clinical and Developmental Immunology, 2012, 2012, 1-8.	3.3	8
57	Distinct Oligoclonal T Cells Are Associated With Graft Versus Host Disease After Stem-Cell Transplantation. Transplantation, 2012, 93, 949-957.	0.5	20
58	Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigenâ€specific cellular immunity. British Journal of Haematology, 2012, 158, 700-711.	1.2	37
59	Favorable Outcomes in Patients with High Donor-Derived T Cell Count after InÂVivo TÂCellâ€“Depleted Reduced-Intensity Allogeneic Stem CellÂTransplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 794-804.	2.0	14
60	Feasibility of risk stratified allocation to single versus tandem autologous SCT in multiple myeloma.. Journal of Clinical Oncology, 2012, 30, e18550-e18550.	0.8	0
61	Fractal Organization of the Human T Cell Repertoire in Health and Following Stem Cell Transplantation. Blood, 2012, 120, 4193-4193.	0.6	2
62	Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation. Journal of Visualized Experiments, 2011, , .	0.2	5
63	Activated NKT Cells and NK Cells Render T Cells Resistant to Myeloid-Derived Suppressor Cells and Result in an Effective Adoptive Cellular Therapy against Breast Cancer in the FVBN202 Transgenic Mouse. Journal of Immunology, 2011, 187, 708-717.	0.4	39
64	Comment on â€œCutting Edge: CD8+ T Cell Priming in the Absence of NK Cells Leads to Enhanced Memory Responsesâ€. Journal of Immunology, 2011, 186, 6071.1-6071.	0.4	2
65	Randomized Phase III Trial of Pegfilgrastim versus Filgrastim after Autologus Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 678-685.	2.0	26
66	Impaired NHEJ function in multiple myeloma. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009, 660, 66-73.	0.4	30
67	Rearrangements of the MLL gene are influenced by DNA secondary structure, potentially mediated by topoisomerase II binding. Genes Chromosomes and Cancer, 2009, 48, 806-815.	1.5	32
68	Dose intense therapy for relapsed lymphoproliferative disorders: the more things change, the more they are the same. Leukemia and Lymphoma, 2009, 50, 682-683.	0.6	0
69	Aprepitant Vs. Placebo Plus Oral Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Associated with Highly Emetogenic Preparative Regimens Prior to Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Double-Blind Phase III Trial.. Blood, 2009, 114, 2267-2267.	0.6	3
70	Effectiveness of Reduced Toxicity Conditioning Regimen with Intravenous Busulfan Plus Pentostatin (BUPENT) in Patients Older Than 50 Years with Advanced Hematologic Malignancies.. Blood, 2009, 114, 3331-3331.	0.6	0
71	Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCT. Bone Marrow Transplantation, 2008, 42, 723-731.	1.3	13
72	Tandem Autologous Stem Cell Transplantation for Patients with Primary Refractory or Poor Risk Recurrent Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2007, 13, 594-600.	2.0	54

#	Article	IF	Citations
73	Alefacept in corticosteroid refractory graft versus host disease: Early results indicate promising activity. Journal of Dermatological Treatment, 2007, 18, 13-18.	1.1	18
74	Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections. Transplant Infectious Disease, 2007, 9, 89-96.	0.7	36
75	Refractory Thrombocytopenia Due to Allo-Immune Anti-CD36 Complicating Unrelated Donor Bone Marrow Transplant in a CD36-Negative Recipient.. Blood, 2007, 110, 4951-4951.	0.6	0
76	Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma. Leukemia and Lymphoma, 2006, 47, 1369-1378.	0.6	59
77	Cardiac nonamyloidotic immunoglobulin deposition disease. Modern Pathology, 2006, 19, 233-237.	2.9	39
78	Patients' understanding of disease status and treatment plan at initial hematopoietic stem cell transplantation consultation. Bone Marrow Transplantation, 2006, 37, 479-484.	1.3	16
79	Autologous hematopoietic stem cell transplants that utilize total body irradiation can safely be carried out entirely on an outpatient basis. Bone Marrow Transplantation, 2006, 38, 757-764.	1.3	22
80	The administration of polymerized human hemoglobin (pyridoxylated) to a jehovah's witness after submyeloablative stem cell transplantation complicated by delayed graft failure. Comprehensive Therapy, 2006, 32, 172-175.	0.2	11
81	Incidence and Risk Factors for Developing Limbic Encephalitis in Allogeneic Stem Cell Transplantation.. Blood, 2006, 108, 2919-2919.	0.6	2
82	The Administration of Polymerized Human Hemoglobin (Pyridoxylated) to a Jehovah's Witness After Submyeloablative Stem Cell Transplantation Complicated by Delayed Graft Failure. Comprehensive Therapy, 2006, 32, 172-175.	0.2	1
83	Second allografts for relapsed hematologic malignancies: feasibility of using a different donor. Bone Marrow Transplantation, 2005, 35, 261-264.	1.3	23
84	Successful Umbilical Cord Blood Transplants in Adults Who Received a Nucleated Cell Dose â‰¥ 1 X 107 Cells/kg Processed by a Post-Thaw Non-Wash Procedure.. Blood, 2005, 106, 2049-2049.	0.6	4
85	Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma. British Journal of Haematology, 2004, 124, 769-776.	1.2	45
86	Post-transplant air-leak syndrome. British Journal of Haematology, 2004, 126, 758-758.	1.2	6
87	Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood, 2004, 104, 3697-3704.	0.6	164
88	Allogeneic Stem Cell Transplantation (SCT) Using Rabbit-ATG (ThymoglobulinÂ®) and 2-Gy Total Body Irradiation (TBI): Reliable Early Engraftment with Minimal Acute Graft Vs. Host Disease (AGVHD).. Blood, 2004, 104, 2312-2312.	0.6	0
89	Expression of Heat Shock Protein 90 and the Effects of HSP90 Inhibitor (17-AAG) in Multiple Myeloma.. Blood, 2004, 104, 4916-4916.	0.6	0
90	Infection - an underappreciated cause of bone pain in multiple myeloma. British Journal of Haematology, 2003, 120, 1047-1050.	1.2	9

#	Article	IF	Citations
91	BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective. Biology of Blood and Marrow Transplantation, 2003, 9, 177-182.	2.0	24
92	BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective. Biology of Blood and Marrow Transplantation, 2003, 9, 177-182.	2.0	10
93	Acquired factor VII deficiency in hematopoietic stem cell transplant recipients. Bone Marrow Transplantation, 2002, 29, 403-408.	1.3	31
94	Actiated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagulation and Fibrinolysis, 2002, 13, 187-192.	0.5	128
95	ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion, 2002, 42, 205-209.	0.8	43
96	Predicting long-term (â‰¥â€ƒ5â€ƒyears) event-free survival in multiple myeloma patients following planned tandem autotransplants. British Journal of Haematology, 2002, 116, 211-217.	1.2	78
97	Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. British Journal of Haematology, 2002, 117, 103-108.	1.2	133
98	Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia, 2002, 16, 1835-1837.	3.3	144
99	Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood, 2001, 98, 1614-1615.	0.6	469
100	High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood, 2001, 97, 2574-2579.	0.6	177
101	Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. British Journal of Haematology, 2001, 112, 242-247.	1.2	56
102	Infections during mobilizing chemotherapy and following autologous stem cell transplantation. Bone Marrow Transplantation, 2001, 28, 1129-1134.	1.3	31
103	T-cell factor-1 expression during human natural killer cell development and in circulating CD56+ bright natural killer cells. Experimental Hematology, 2001, 29, 499-506.	0.2	11
104	Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation. Bone Marrow Transplantation, 2000, 26, 315-320.	1.3	42